- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Genetic · Drug
- Lead sponsor
- Vector Y Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 838
matching trials from the live ClinicalTrials.gov search.
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 75
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
- Conditions
- Chronic Granulomatous Disease
- Interventions
- Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 55 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Giant Axonal Neuropathy (GAN)
- Interventions
- scAAV9/JeT-GAN
- Genetic
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Variant Late-Infantile Neuronal Ceroid Lipofuscinosis
- Interventions
- AT-GTX-501
- Genetic
- Lead sponsor
- Emily de los Reyes
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Carcinoma, Transitional Cell, Bladder Neoplasms
- Interventions
- Oncolytic adenovirus (serotype 5) - CG0070
- Biological
- Lead sponsor
- Cell Genesys
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • San Francisco, California • Billings, Montana + 5 more
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- ADA PBSC, ADA Umbilical Cord Blood Cells, Transduced Lymphocytes
- Drug
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1990 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
- Interventions
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Biological · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Peripheral Vascular Diseases
- Interventions
- riferminogene pecaplasmid, Placebo (for riferminogene pecaplasmid)
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
- Interventions
- CGF166
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Baltimore, Maryland • New York, New York + 1 more
- Conditions
- X-linked Hypophosphatemia
- Interventions
- KK8123
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 5
- States / cities
- San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more
- Conditions
- Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Monomorphic Epithelialtropic Intestinal Lymphoma, Enteropathy Associated T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Mycosis Fungoides, Subacute Panniculitis-like T-cell Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2044
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Severe Combined Immunodeficiency Disease, X-linked
- Interventions
- CL20-i4-EF1α-hγc-OPT, Busulfan, CliniMacs
- Genetic · Drug · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Months · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2034
- U.S. locations
- 3
- States / cities
- San Francisco, California • Memphis, Tennessee • Seattle, Washington
- Conditions
- Congestive Heart Failure
- Interventions
- Ad5.hAC6, Sucrose (3%)
- Drug
- Lead sponsor
- Hammond, H. Kirk, M.D.
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 7
- States / cities
- San Diego, California • Chicago, Illinois • Minneapolis, Minnesota + 3 more
- Conditions
- Arthritis, Rheumatoid, Arthritis, Psoriatic, Ankylosing Spondylitis
- Interventions
- tgAAC94 gene therapy vector, tgAAC94 placebo
- Genetic
- Lead sponsor
- Targeted Genetics Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 22
- States / cities
- Glendale, Arizona • Tuscon, Arizona • Palm Desert, California + 18 more
- Conditions
- Huntington's Disease
- Interventions
- intra-striatal rAAV5-miHTT, Imitation (sham) surgery
- Genetic · Other
- Lead sponsor
- UniQure Biopharma B.V.
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 9 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- delandistrogene moxeparvovec, placebo
- Genetic
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more
- Conditions
- Lymphoma
- Interventions
- RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Procedure
- Lead sponsor
- Systemix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 2 more
- Conditions
- Melanoma, Skin Cancer
- Interventions
- autologous anti-MART-1 F5 T-cell receptor, Cyclophosphamide, Fludarabine, Aldesleukin, autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease
- Interventions
- AAV2-GDNF gene therapy, control surgery
- Drug · Procedure
- Lead sponsor
- AskBio Inc
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more
- Conditions
- Krabbe Disease
- Interventions
- FBX-101
- Biological
- Lead sponsor
- Forge Biologics, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hypercholesterolemia, Familial
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 14 participants
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Atlanta, Georgia • Columbus, Ohio